Swiss pharma giant Novartis (NOVN: VX) has expanded its partnership with the Medicines for Malaria Venture (MMV).
Novartis will lead the development of antimalarial compound KAF156, with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation.
KAF156 has been hailed as a next-generation treatment that looks set to fight the growing problem of drug resistance. It belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze